Hydroxychloroquine retinopathy: An emerging problem

Eye (Basingstoke)

Volumn 31, Issue 6, 2017, Pages 972-976

  Latasiewicz, M ^a   Gourier, H ^a   Yusuf, I H ^a   Luqmani, R ^b   Sharma, S M ^a   Downes, S M ^a  

^a OXFORD EYE HOSPITAL   (United Kingdom)

^b NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLCHICINE; FENOFIBRATE; FOLIC ACID; FUROSEMIDE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; LORATADINE; LOSARTAN; METHOTREXATE; OMEPRAZOLE; PROBENECID; TAMOXIFEN; ANTIRHEUMATIC AGENT;

ADULT; AGED; ARTICLE; AUTOFLUORESCENCE IMAGING; CASE REPORT; CASE STUDY; DISEASE SEVERITY; DRUG MONITORING; FEMALE; HUMAN; MIDDLE AGED; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; RETINOPATHY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCANNING LASER OPHTHALMOSCOPY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VISUAL FIELD; VISUAL FIELD DEFECT; CHEMICALLY INDUCED; DRUG EFFECTS; EARLY DIAGNOSIS; ELECTRORETINOGRAPHY; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; FORECASTING; PATHOLOGY; PATHOPHYSIOLOGY; PERIMETRY; RETINA; RETINA DISEASE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EARLY DIAGNOSIS; ELECTRORETINOGRAPHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FORECASTING; FUNDUS OCULI; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RETINA; RETINAL DISEASES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL FIELD TESTS; VISUAL FIELDS;

EID: 85020448831     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2016.297     Document Type: Article

References (12)

1. Grupper C, Bregeat P, Juge P. [SEvere retinopathy during treatment of lupus erythematosus by synthetic antimalarials (2 cases)]. Bull Soc Fr Dermatol Syphiligr 1963; 70: 824-832.
2. Nika M, Blachley TS, Edwards P, Lee PP, Stein JD. Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. JAMA Ophthalmol 2014; 132: 1199-1208.
3. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016; 123: 1386-1394.
4. Chen E, Brown DM, Benz MS, Fish RH, Wong TP, Kim RY et al. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the 'flying saucer' sign). Clin Ophthalmol 2010; 4: 1151-1158.
5. Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007; 66: 1168-1172.
6. Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 2003; 110: 1321-1326.
7. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014; 132: 1453-1460.
8. The Royal College of Ophthalmologists. Hydroxychloroquine and Ocular Toxicity Recommendations on Screening, The Royal College of Ophthalmologists, 2009. Available at: https:// www.rcophth.ac.uk/wp-content/uploads/2014/12/2009-SCI-010-Ocular-Toxicity.pdf (accessed on 16 September 2016).
9. Mititelu M, Wong BJ, Brenner M, Bryar PJ, Jampol LM, Fawzi AA. Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. JAMA Ophthalmol 2013; 131: 1187-1197.
10. Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye 2017 (in press); doi:10.1038/eye.2016.298.
11. Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 2015; 122: 110-116.
12. Lee DH, Melles RB, Joe SG, Lee JY, Kim JG, Lee CK et al. Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology 2015; 122: 1252-1256.